Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.
Takaki S, Kurosaki M, Mori N, Tsuji K, Ochi H, Marusawa H, Nakamura S, Tada T, Narita R, Uchida Y, Akahane T, Kondo M, Kusakabe A, Furuta K, Kobashi H, Arai H, Nonogi M, Tamada T, Hasebe C, Ogawa C, Sato T, Tamaki N, Yasui Y, Tsuchiya K, Izumi N.
Takaki S, et al. Among authors: izumi n.
Invest New Drugs. 2023 Apr;41(2):340-349. doi: 10.1007/s10637-023-01349-4. Epub 2023 Mar 30.
Invest New Drugs. 2023.
PMID: 36995548